Showing results (51-60 of 453) with videos related to
Sort By:
Pageof 46
Annual Review of Medicine|October 13, 2021
A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 BlockadeNatalie Y L Ngoi, Guang Peng, Timothy A YapCancer Research|December 1, 2018
Development of PARP and Immune-Checkpoint Inhibitor CombinationsRoss A Stewart, Patrick G Pilié, Timothy A YapJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2013
Development of therapeutic combinations targeting major cancer signaling pathwaysTimothy A Yap, Aurelius Omlin, Johann S de BonoNature Reviews. Cancer|February 25, 2009
Beyond chemotherapy: targeted therapies in ovarian cancerTimothy A Yap, Craig P Carden, Stan B KayeTranslational Oncogenomics|November 27, 2015
Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical TrialsJuanita Lopez, Sam Harris, Desam Roda, et al.Current Opinion in Oncology|May 21, 2010
PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancersCraig P Carden, Timothy A Yap, Stan B KayeThe EPMA Journal|June 29, 2012
Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon?Timothy A Yap, Charles Swanton, Johann S de BonoVeterinary Research|September 2, 2022
Evaluation of alpaca tracheal explants as an ex vivo model for the study of Middle East respiratory syndrome coronavirus (MERS-CoV) infectionNigeer Te, Jordi Rodon, Rhea Creve, et al.Microbes and Infection|November 19, 2023
Middle East respiratory coronavirus (MERS-CoV) internalized by llama alveolar macrophages does not result in virus replication or induction of pro-inflammatory cytokinesJordi Rodon, Martin Sachse, Nigeer Te, et al.Cancer Treatment Reviews|February 24, 2017
The expanding role of immunotherapyJuan Martin-Liberal, María Ochoa de Olza, Cinta Hierro, et al.Pageof 46